ReNeuron Group plc (RNUGF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.4 Million GBP | 44.18% |
| 2022 | -9.68 Million GBP | 14.61% |
| 2021 | -11.34 Million GBP | 0.57% |
| 2020 | -11.41 Million GBP | 20.15% |
| 2019 | -14.29 Million GBP | 18.86% |
| 2018 | -17.61 Million GBP | -13.11% |
| 2017 | -15.57 Million GBP | -37.16% |
| 2016 | -11.35 Million GBP | -27.49% |
| 2015 | -8.9 Million GBP | -26.04% |
| 2014 | -7.06 Million GBP | -11.36% |
| 2013 | -6.34 Million GBP | -1.86% |
| 2012 | -6.22 Million GBP | -1.32% |
| 2011 | -6.14 Million GBP | -5.09% |
| 2010 | -5.85 Million GBP | -59.53% |
| 2009 | -3.66 Million GBP | 44.2% |
| 2008 | -6.57 Million GBP | -25.2% |
| 2007 | -5.24 Million GBP | 17.59% |
| 2006 | -6.36 Million GBP | -98.16% |
| 2005 | -3.21 Million GBP | -295.33% |
| 2004 | -813 Thousand GBP | 81.67% |
| 2003 | -4.43 Million GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.42 Million GBP | 36.36% |
| 2024 Q2 | -1.42 Million GBP | 0.0% |
| 2023 FY | -5.4 Million GBP | 44.18% |
| 2023 Q4 | -2.23 Million GBP | -100.0% |
| 2023 Q2 | -3.17 Million GBP | -100.0% |
| 2023 Q1 | -1.58 Million GBP | 64.35% |
| 2023 Q3 | -1.11 Million GBP | 64.86% |
| 2022 Q4 | -4.45 Million GBP | -100.0% |
| 2022 Q3 | -2.22 Million GBP | 57.44% |
| 2022 FY | -9.68 Million GBP | 14.61% |
| 2022 Q1 | -2.61 Million GBP | 38.5% |
| 2022 Q2 | -5.23 Million GBP | -100.0% |
| 2021 Q1 | -3.54 Million GBP | 52.81% |
| 2021 FY | -11.34 Million GBP | 0.57% |
| 2021 Q4 | -4.25 Million GBP | -100.0% |
| 2021 Q3 | -2.12 Million GBP | 70.0% |
| 2021 Q2 | -7.09 Million GBP | -100.0% |
| 2020 Q2 | -3.89 Million GBP | -100.0% |
| 2020 Q4 | -7.51 Million GBP | -100.0% |
| 2020 Q1 | -1.94 Million GBP | 56.64% |
| 2020 FY | -11.41 Million GBP | 20.15% |
| 2020 Q3 | -3.75 Million GBP | 3.58% |
| 2019 Q3 | -4.49 Million GBP | -67.69% |
| 2019 Q1 | -2.68 Million GBP | 33.38% |
| 2019 FY | -14.29 Million GBP | 18.86% |
| 2019 Q4 | -4.49 Million GBP | 0.0% |
| 2019 Q2 | -2.68 Million GBP | 0.0% |
| 2018 Q3 | -4.02 Million GBP | 15.92% |
| 2018 Q2 | -4.78 Million GBP | 0.0% |
| 2018 Q1 | -4.78 Million GBP | -21.46% |
| 2018 FY | -17.61 Million GBP | -13.11% |
| 2018 Q4 | -4.02 Million GBP | 0.0% |
| 2017 Q2 | -3.84 Million GBP | 0.0% |
| 2017 FY | -15.57 Million GBP | -37.16% |
| 2017 Q1 | -3.84 Million GBP | -11.94% |
| 2017 Q3 | -3.93 Million GBP | -2.38% |
| 2017 Q4 | -3.93 Million GBP | 0.0% |
| 2016 Q1 | -2.24 Million GBP | 6.24% |
| 2016 FY | -11.35 Million GBP | -27.49% |
| 2016 Q4 | -3.43 Million GBP | 0.0% |
| 2016 Q3 | -3.43 Million GBP | -53.44% |
| 2016 Q2 | -2.24 Million GBP | 0.0% |
| 2015 Q1 | -2.06 Million GBP | -5.87% |
| 2015 Q4 | -2.38 Million GBP | 0.0% |
| 2015 Q3 | -2.38 Million GBP | -15.75% |
| 2015 Q2 | -2.06 Million GBP | 0.0% |
| 2015 FY | -8.9 Million GBP | -26.04% |
| 2014 Q1 | -1.58 Million GBP | 8.65% |
| 2014 FY | -7.06 Million GBP | -11.36% |
| 2014 Q4 | -1.94 Million GBP | 0.0% |
| 2014 Q3 | -1.94 Million GBP | -23.11% |
| 2014 Q2 | -1.58 Million GBP | 0.0% |
| 2013 Q4 | -1.73 Million GBP | 0.0% |
| 2013 Q3 | -1.73 Million GBP | 0.0% |
| 2013 FY | -6.34 Million GBP | -1.86% |
| 2012 FY | -6.22 Million GBP | -1.32% |
| 2011 FY | -6.14 Million GBP | -5.09% |
| 2010 FY | -5.85 Million GBP | -59.53% |
| 2009 FY | -3.66 Million GBP | 44.2% |
| 2008 FY | -6.57 Million GBP | -25.2% |
| 2007 FY | -5.24 Million GBP | 17.59% |
| 2006 FY | -6.36 Million GBP | -98.16% |
| 2005 FY | -3.21 Million GBP | -295.33% |
| 2004 FY | -813 Thousand GBP | 81.67% |
| 2003 FY | -4.43 Million GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -304.963% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 108.303% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -755.145% |
| Nascent Biotech, Inc. | -2.08 Million USD | -159.043% |
| Qrons Inc. | -789.34 Thousand USD | -585.123% |
| Regen BioPharma, Inc. | 1.02 Million USD | 628.379% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 110.208% |
| BioStem Technologies, Inc. | -8.48 Million USD | 36.249% |
| Skye Bioscience, Inc. | -37.64 Million USD | 85.634% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1201.63% |
| Rebus Holdings, Inc. | -1.02 Million USD | -430.196% |
| CSL Limited | 2.64 Billion USD | 100.205% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 91.361% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -41.608% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 65.926% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 22.553% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 92.786% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 17.763% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1878.04% |
| SQZ Biotechnologies Company | -79.46 Million USD | 93.194% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -86.973% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -197.057% |
| Mesoblast Limited | -87.95 Million USD | 93.851% |
| Marizyme, Inc. | -65.34 Million USD | 91.724% |
| Genus plc | 7.9 Million USD | 168.456% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 50.348% |
| Pharming Group N.V. | -10.54 Million USD | 48.73% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -149.238% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -45.759% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 38.851% |
| ContraFect Corporation | -65.15 Million USD | 91.7% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -10.682% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -213.062% |
| IMV Inc. | -36.48 Million USD | 85.178% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 32.901% |
| MultiCell Technologies, Inc. | -380.07 USD | -1422795.782% |
| ONE Bio Corp. | 8.67 Million USD | 162.328% |
| Accustem Sciences Inc. | -3.74 Million USD | -44.351% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 89.538% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -326.79% |
| Q BioMed Inc. | -2.05 Million USD | -163.536% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -44.87% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -127.144% |
| Biomind Labs Inc. | -1.21 Million USD | -345.352% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 90.945% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -74.352% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 31.571% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -177.44% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -36011.111% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 7.035% |
| GB Sciences, Inc. | -1.36 Million USD | -297.157% |
| Alpha Cognition Inc. | -13.77 Million USD | 60.734% |
| HST Global, Inc. | -146.21 Thousand USD | -3598.789% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -208.188% |
| Halberd Corporation | -79.67 Thousand USD | -6687.489% |
| Enzolytics Inc. | -2.17 Million USD | -148.434% |
| Agentix Corp. | -1.37 Million USD | -293.535% |
| Resverlogix Corp. | -3.61 Million USD | -49.806% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -70.522% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.167% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 5618.367% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 178.098% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -36.119% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -78.71% |
| AVAX Technologies, Inc. | -6.41 Million USD | 15.68% |
| Zenith Capital Corp. | -10.59 Million USD | 48.962% |
| Genscript Biotech Corporation | -95.47 Million USD | 94.336% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -23168.221% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -30.441% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -8847.626% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -169.71% |
| Kadimastem Ltd | -3.3 Million USD | -63.512% |
| Helix BioMedix, Inc. | -1.05 Million USD | -412.094% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1125.279% |
| LadRx Corporation | 400.44 Thousand USD | 1450.504% |
| Cell Source, Inc. | -5.32 Million USD | -1.631% |
| Regen BioPharma, Inc. | 1.02 Million USD | 628.379% |
| NovAccess Global Inc. | -4.76 Million USD | -13.395% |
| Affymax, Inc. | -14.42 Million USD | 62.507% |
| Itoco Inc. | -1.86 Million USD | -189.353% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -21.732% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -224.026% |
| Mobile Lads Corp. | -2.26 Million USD | -138.944% |
| CytoDyn Inc. | -49.84 Million USD | 89.149% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -6742.711% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2270.609% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -474.385% |
| SYBLEU INC | -180.3 Thousand USD | -2899.379% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -235.331% |
| International Stem Cell Corporation | -131 Thousand USD | -4028.244% |
| Bioxytran, Inc. | -4.28 Million USD | -26.355% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -9864.623% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -113.734% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 88.75% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -155.818% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -592.546% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -70.707% |
| Neutra Corp. | -233.46 Thousand USD | -2216.407% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 73.348% |
| PureTech Health plc | -65.69 Million USD | 91.768% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 74.57% |
| IXICO plc | -1.17 Million USD | -359.083% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 45.522% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 90.534% |
| CSL Limited | 2.64 Billion USD | 100.205% |
| Cellectis S.A. | -103.17 Million USD | 94.758% |